A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease. BAN2401-G000-201
The purpose of this study is to learn more about Alzheimer’s disease and a drug called BAN2401. This study is designed to determine if the study drug has a benefit on a person’s cognitive status, and to assess the safety and tolerability of the study drug for subjects with early Alzheimer’s disease (Mild Cognitive Impairment due to Alzheimer’s disease or mild Alzheimer’s disease).
• Male or Female from the ages of 50 to 90 years
• Must have a diagnosis of Mild Cognitive Impairment or mild Alzheimer's Disease.
• No significant, uncontrolled additional medical conditions.
• No history of stroke.
• If taking an acetylcholinesterase inhibitor and/or memantine, must be on a stable dose.
• Must have a study partner.
• Must be able to undergo MRI scanning
50 - 90
Healthy Volunteers Needed
Duration of Participation
23 months, 43 visits (plus 1 PET scan, 9 MRI, and 3 optional lumbar punctures)
Subjects will be reimbursed for transportation for each study visit completed. The amount will vary based on the procedures performed at that visit.